Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Regorafenib monohydrate
Cat. No.:
OB0225LY-0339
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and LC-MS.
Size:
Product Overview
Description:
Regorafenib monohydrate is an oral multikinase inhibitor that inhibits a variety of tumor-associated enzymes.
Synonym:
1019206-88-2; Regorafenib; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; Regorafenibum; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
CAS No.:
1019206-88-2
Compound CID:
11167602
Formula:
C21H17ClF4N4O4
Formula Weight:
500.83
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Regorafenib monohydrate can be used in cancer research to help understand the mechanisms of tumor growth as well as to find new therapeutic targets.
Library Information
Targets:
Receptor tyrosine kinases; Serine/Threonine kinases
Receptors:
B-RAF; Kit; VEGFR2; VEGFR3; PDGFRβ; RAF-1; RET
Pathways:
MAPK; Autophagy; Tyrosine kinase/adaptors; Angiogenesis; Apoptosis
Plate Number:
AOCL-5
Plate Location:
d3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
20 mg/mL; 39.93 mM
ALogP:
4.174
HBA_Count:
4
HBD_Count:
3
Rotatable Bond:
6
